HistoScanning is a proprietary tissue differentiation, visualization and measurement technology designed to assist specialists in identifying changes to solid organ tissues. The technology works in conjunction with Transrectal Ultrasound (TRUS) procedures and extracts new information from prostate ultrasound data. It adds an important new dimension to the practice of prostate examination as well as prostate biopsy indication and acquisition.
By entering into this collaboration, B-K Medical aims to retain and expand market leadership by continuing to support and be at the forefront of the latest technological advances in prostate ultrasound.
Michael Brock, B-K Medical's President, stated: "We take our position as the innovators in prostate ultrasound imaging seriously. We believe that being the market leader reflects our commitment to identifying and developing the latest technological advances for the good of our customers and their patients. HistoScanning has the potential to be the major diagnostic modality of the future, increasing the efficiency and diagnostic value of prostate ultrasound."
For Advanced Medical Diagnostics, the agreement facilitates introduction of its technology to major global markets. Dror Nir, Chief Executive Officer of Advanced Medical Diagnostics and inventor of the HistoScanning technology, pointed out: "We want to make sure that HistoScanning will realize its potential. It means working together with companies who share our vision of non-invasive tissue characterization and are committed to investing in moving medicine forward." He went on to stress that "B-K is long recognized for its commitment to and leadership in urological ultrasound, and it shares our view on how HistoScanning addresses the major clinical challenges in prostate patient management."
The British Journal of Urology recently published a study conducted on men whose prostate biopsies tested positive and whose prostates were later surgically removed. This study showed that in the study population, HistoScanning correctly identified the largest tumours, accurately measured their diameters and correctly attributed the presence of multiple foci, the laterality of the disease, and the involvement of the prostate capsule.
Under the guidance of an international panel of clinical thought leaders, Advanced Medical Diagnostics is supporting several multi-centre studies in reference centres across Europe to provide additional clinical evidence to validate the role of HistoScanning in routine clinical practice.
The first joint presentation of HistoScanning will be at the upcoming 23rd Annual European Association of Urology (EAU) Congress in Milan, Italy, March 26-29, 2008. HistoScanning for the prostate is expected to be commercially introduced in Europe later this year.
B-K Medical ApS, a wholly owned subsidiary of Analogic Corporation, specializes in the development and production of diagnostic ultrasound equipment. The company is recognized as a world expert in developing ultrasound scanners specially designed for surgery and for the investigation of urological disorders. The product line also includes scanners for other applications, such as gynaecological examinations, foetal scanning, and radiology.
B-K Medical is represented in 60 countries, with subsidiary sales companies in the United States, Belgium, Germany, Italy, Norway, Sweden and the United Kingdom. An extensive network of distributors connects B-K Medical with Eastern Europe, the Middle East, Asia and the rest of the world. The company has about 300 employees, of which about two-thirds are located in Denmark.
Advanced Medical Diagnostics S.A. is a privately held company based in Waterloo, Belgium. The company is dedicated to improving cancer diagnostics in a clinically meaningful and cost-effective manner. A dynamic and culturally diverse team of 20 experienced scientists, engineers and business professionals are committed to bringing HistoScanning to medical specialists and their patients around the world.